CL2021002111A1 - Composición para vacuna viva atenuada contra la influenza y proceso para su preparación. - Google Patents
Composición para vacuna viva atenuada contra la influenza y proceso para su preparación.Info
- Publication number
- CL2021002111A1 CL2021002111A1 CL2021002111A CL2021002111A CL2021002111A1 CL 2021002111 A1 CL2021002111 A1 CL 2021002111A1 CL 2021002111 A CL2021002111 A CL 2021002111A CL 2021002111 A CL2021002111 A CL 2021002111A CL 2021002111 A1 CL2021002111 A1 CL 2021002111A1
- Authority
- CL
- Chile
- Prior art keywords
- laiv
- strains
- live attenuated
- composition
- devoid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación proporciona composiciones y métodos para la fabricación y obtención de una composición para una vacuna viva atenuada contra la influenza (LAIV) que se puede administrar por vía intranasal para proporcionar protección contra la infección por el virus de la influenza. Dichas cepas de LAIV se basan en fenotipos adaptados al frío, sensibles a la temperatura y atenuados de virus donantes maestros (MGV) que contienen los genes de glicoproteínas superficiales de las cepas de influenza estacional o pandemia de tipo salvaje. Además, dichas cepas de LAIV están más adaptadas para crecer en células MDCK (células renales caninas Madin Darby). El uso de huevos se evita en la fabricación de vacunas a gran escala. El proceso de purificación está desprovisto de pasos de cromatografía. Dicha composición de LAIV incluye uno o más virus vivos atenuados de la vacuna contra la influenza y está desprovista de polímeros y tensioactivos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201921006071 | 2019-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021002111A1 true CL2021002111A1 (es) | 2022-01-28 |
Family
ID=69740470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021002111A CL2021002111A1 (es) | 2019-02-15 | 2021-08-11 | Composición para vacuna viva atenuada contra la influenza y proceso para su preparación. |
Country Status (20)
Country | Link |
---|---|
US (1) | US20220211837A1 (es) |
EP (1) | EP3924052A1 (es) |
JP (1) | JP2022520443A (es) |
KR (1) | KR20210129073A (es) |
CN (1) | CN113646047A (es) |
AR (1) | AR119691A1 (es) |
AU (1) | AU2020222113A1 (es) |
BR (1) | BR112021016059A2 (es) |
CA (1) | CA3130036A1 (es) |
CL (1) | CL2021002111A1 (es) |
CO (1) | CO2021010751A2 (es) |
IL (1) | IL285526A (es) |
JO (1) | JOP20200037A1 (es) |
MA (1) | MA54942A (es) |
MX (1) | MX2021009837A (es) |
PE (1) | PE20212322A1 (es) |
SG (1) | SG11202108766RA (es) |
TW (1) | TW202045205A (es) |
UY (1) | UY38587A (es) |
WO (1) | WO2020165912A1 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU764368B2 (en) * | 1999-09-24 | 2003-08-14 | Smithkline Beecham Biologicals (Sa) | Intranasal influenza virus vaccine |
CA2738022A1 (en) * | 2008-09-24 | 2010-04-01 | Medimmune, Llc | Methods for cultivating cells, propagating and purifying viruses |
TWI670085B (zh) * | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
EP3655000A4 (en) * | 2017-07-11 | 2021-07-14 | Universal Stabilization Technologies, Inc. | PROCESS FOR THE PRESERVATION OF BIOPHARMACEUTICALS |
-
2020
- 2020-02-07 BR BR112021016059-0A patent/BR112021016059A2/pt unknown
- 2020-02-07 SG SG11202108766RA patent/SG11202108766RA/en unknown
- 2020-02-07 MX MX2021009837A patent/MX2021009837A/es unknown
- 2020-02-07 CA CA3130036A patent/CA3130036A1/en active Pending
- 2020-02-07 AU AU2020222113A patent/AU2020222113A1/en active Pending
- 2020-02-07 EP EP20708683.6A patent/EP3924052A1/en active Pending
- 2020-02-07 CN CN202080024926.8A patent/CN113646047A/zh active Pending
- 2020-02-07 KR KR1020217027060A patent/KR20210129073A/ko active Search and Examination
- 2020-02-07 WO PCT/IN2020/050121 patent/WO2020165912A1/en active Application Filing
- 2020-02-07 MA MA054942A patent/MA54942A/fr unknown
- 2020-02-07 PE PE2021001342A patent/PE20212322A1/es unknown
- 2020-02-07 JP JP2021547436A patent/JP2022520443A/ja active Pending
- 2020-02-07 US US17/429,965 patent/US20220211837A1/en active Pending
- 2020-02-14 TW TW109104708A patent/TW202045205A/zh unknown
- 2020-02-14 AR ARP200100405A patent/AR119691A1/es unknown
- 2020-02-14 UY UY0001038587A patent/UY38587A/es unknown
- 2020-02-16 JO JOP/2020/0037A patent/JOP20200037A1/ar unknown
-
2021
- 2021-08-11 IL IL285526A patent/IL285526A/en unknown
- 2021-08-11 CL CL2021002111A patent/CL2021002111A1/es unknown
- 2021-08-13 CO CONC2021/0010751A patent/CO2021010751A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
UY38587A (es) | 2020-09-30 |
WO2020165912A1 (en) | 2020-08-20 |
MX2021009837A (es) | 2021-09-10 |
PE20212322A1 (es) | 2021-12-14 |
EP3924052A1 (en) | 2021-12-22 |
JP2022520443A (ja) | 2022-03-30 |
CO2021010751A2 (es) | 2021-09-09 |
US20220211837A1 (en) | 2022-07-07 |
SG11202108766RA (en) | 2021-09-29 |
TW202045205A (zh) | 2020-12-16 |
AU2020222113A1 (en) | 2021-10-07 |
JOP20200037A1 (ar) | 2020-08-15 |
BR112021016059A2 (pt) | 2021-10-13 |
CA3130036A1 (en) | 2020-08-20 |
CN113646047A (zh) | 2021-11-12 |
MA54942A (fr) | 2021-12-22 |
KR20210129073A (ko) | 2021-10-27 |
IL285526A (en) | 2021-09-30 |
AR119691A1 (es) | 2022-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Easterbrook et al. | Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice | |
BARBERIS et al. | History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines | |
Tian et al. | Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics | |
MX2010003202A (es) | Metodo para producir virus de la gripe. | |
Noh et al. | Influenza vaccines: unmet needs and recent developments | |
Becker et al. | Influenza vaccines: successes and continuing challenges | |
BR112012020839A2 (pt) | vacinas para uso na profilaxe e tratamento de doença de vírus da influenza | |
AR069883A1 (es) | Virus de la estomatitis vesicular geneticamente modificado, composicion inmunogenica que lo comprende, metodo para producirlo, metodos para adaptar un virus para crecer en el cultivo de cedula y para proteger un mamifero contra la infeccion con un organismo patogeno | |
UY37179A (es) | Composiciones producidas por microorganismos con actividad estimuladora sobre las plantas | |
Shaw | New technologies for new influenza vaccines | |
Ren et al. | H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus | |
NZ739260A (en) | Inactivated canine influenza vaccines and methods of making and uses thereof | |
AR115069A1 (es) | Virus vacuna quimérico sintético | |
Wohlbold et al. | An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13 | |
Nishi et al. | Genetic analysis of an H5N2 highly pathogenic avian influenza virus isolated from a chicken in a live bird market in Northern Vietnam in 2012 | |
CL2021002111A1 (es) | Composición para vacuna viva atenuada contra la influenza y proceso para su preparación. | |
ŠANTAK | Old and new ways to combat human influenza virus | |
Zhou et al. | High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1 | |
US20220160863A1 (en) | High growth influenza virus | |
Wendel et al. | SnapShot: evolution of human influenza A viruses | |
Lin et al. | Analysis of the phylogeny of Chinese H9N2 avian influenza viruses and their pathogenicity in mice | |
Horimoto et al. | Designing vaccines for pandemic influenza | |
Su et al. | Emergence and pandemic potential of avian influenza a (H7N9) virus | |
AR085800A1 (es) | Vacuna de rinitis equina | |
Ruan et al. | Protective efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the European Avian-like H1N1 swine influenza virus in mice and pigs |